Access90: Inflation Reduction Act Insight Series – Biosimilars: A Key Question Answered (Part 1)
How will the Inflation Reduction Act effect manufacturers of both originator drugs and biosimilars? According to PRECISIONvalue expert Amy Martin, a range of unintended consequences may impact pricing, innovation—and ultimately the therapies available to patients. Watch this short video to see why.
PRECISION is named a RECOGNIZED INNOVATOR twice in PM360 Magazine’s 2023 Innovators Issue
PRECISION is named a RECOGNIZED INNOVATOR twice in PM360 Magazine’s 2023 Innovators Issue for our Access Genius Insights and Navigator365 Core and Cx Benchmark technologies.
Access Genius combines best-in-class technology and unmatched data synthesis in a smart pharmaceutical market access messaging platform.
The Navigator365 suite of HCP insight products provide the tools and evidence clients need to answer key business questions and deliver a signature brand experience for their customers and patients.
Read more about how these innovative technologies in PM360’s Innovators Issue HERE.
Precision Medicine Group Releases Its Inaugural Environmental, Social and Governance (ESG) Report
Precision is proud to have published our inaugural 2023 Environmental, Social and Governance (ESG) Report, reflecting the company’s ongoing efforts to do better for our people, in our practices, and with the broader community at large. This year’s report shares key achievements, performance metrics, and steps we have taken to enhance sustainability throughout the company, including:
· Engaging internal and external stakeholders in our company’s first ESG materiality assessment to identify and prioritize our material issues
· Defining Precision’s approach to ESG in our company’s ESG Strategy Statement · Creating a three-year strategic ESG Roadmap for advancing our performance across environmental, social, and governance issues · Initiating energy efficiency projects and standards across our facilities
· Implementing implicit bias training for our Executive Leadership Team and Human Resources leaders
· Contributing volunteer hours by over 425 employees and over $250,000 in donations to more than 70 charitable foundations and causes
Article: Anshul Mangal of Project Farma Discusses Policy Strategies to Address the Current Cancer Drug Shortage
In September, the American Association for Cancer Research reported that hospitals are facing the worst chemotherapy drug shortage crisis the US has ever seen. Anshul Mangal, President of Project Farma, sat down with AJMC to address the primary reasons for the current cancer drug shortages and how Project Farma is helping to address these challenges.
Article: How Patients and Caregivers Can Be a Catalyst for Rare Disease Innovation
There are approximately 7000 rare diseases affecting 30 million individuals in the United States and up to 250 million individuals worldwide. The unmet medical need for individuals living with these conditions has made this a very active area for research and development. Precision’s Phil Cyr discusses how patients and caregivers can be a catalyst for rare disease innovation.
White Paper: Unleashing the Power of Precision Medicine: Radioligand Therapy
This article was originally published on This Month in Transformative Medicine on October 17, 2023
The current standard of cancer care has saved many lives, but these methods often come with incredibly difficult side effects. Advancements in technology have brought new options to cancer care that hope to provide meaningful outcomes while minimizing the impact to the patient’s quality of life.
In this white paper Anshul Mangal, President of Project Farma (PF) & Precision ADVANCE, and Sumit Verma, Co-founder and Partner at Orchestra Life Sciences, discuss the power and potential of radioligand therapies and its impact on the treatment of a number of cancers.
Article: Battling the Cancer Drug Shortage: Q&A With Anshul Mangal, President of Project Farma and Precision Advance
How can our industry address the root causes for the current cancer drug shortages, and how can we prepare and avoid these shortages? Anshul Mangal, President of Project Farma and Precision ADVANCE, sat down with PharmExec.com to share answers.
On Demand: State of the Union for Advanced Therapies
Sponsored by Precision ADVANCE, this Endpoints webinar will convene industry leaders to discuss the current state of the industry, and the future of advanced therapies including innovations in research and development, going from treating rare diseases to prevalent conditions, continued investment, and next-generation technologies. The panelists will also discuss manufacturing and talent bottlenecks, and innovative reimbursement payment models. This discussion will be moderated by Anshul Mangal: President (Precision ADVANCE & Project Farma), and included insights from Dan Kirby: Chief Commercial Officer (Orca Bio), Deborah Phippard: CSO (Precision for Medicine), and additional panelists.
Medicare Drug Price Negotiation: First 10 Drugs Announced
Download the latest IRA Special Edition Update — Medicare Drug Price Negotiation: First 10 Drugs Announced. These drugs accounted for $50.5 billion in Medicare Part D spending from June 2022 to May 2023. So what happens next?
Download Now: Precision October Events Calendar
The PV&H October Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
